Risk for PML in Multiple Sclerosis Predicted With Anti-JCV Antibody Index
While an efficacious treatment for relapsing MS, natalizumab is associated with risk of developing progressive multifocal leukoencephalopathy.
A cohort study evaluated the effects of smoking on disease activity in interferon beta-treated relapsing-remitting multiple sclerosis.
The impact of treatment with dimethyl fumarate and fingolimod on lymphocyte and leukocyte count was evaluated in patients with multiple sclerosis.
Risk of multiple sclerosis may be reduced with high sun exposure.